Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Cut to $78.00 by Analysts at Needham & Company LLC

Xenon Pharmaceuticals (NASDAQ:XENE) had its price objective reduced by Needham & Company LLC from $80.00 to $78.00 in a research note published on Friday, MarketBeat.com reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts have also weighed in on XENE. JPMorgan Chase & Co. boosted their target price on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a report on Friday, January 9th. Wells Fargo & Company boosted their price target on Xenon Pharmaceuticals from $49.00 to $68.00 and gave the company an “overweight” rating in a research note on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft boosted their price target on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Finally, Wedbush reduced their price target on Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday, March 16th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $74.50.

Xenon Pharmaceuticals Stock Performance

Shares of Xenon Pharmaceuticals stock opened at $56.44 on Friday. The business’s 50 day simple moving average is $54.64 and its 200 day simple moving average is $46.62. Xenon Pharmaceuticals has a 52-week low of $28.19 and a 52-week high of $63.95. The firm has a market cap of $5.45 billion, a PE ratio of -12.01 and a beta of 0.65.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting the consensus estimate of ($1.17). During the same period last year, the business posted ($0.83) EPS. As a group, equities research analysts predict that Xenon Pharmaceuticals will post -4.83 EPS for the current year.

Insider Activity

In related news, CEO Ian Mortimer sold 7,308 shares of the company’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $55.23, for a total transaction of $403,620.84. Following the sale, the chief executive officer owned 19,923 shares in the company, valued at $1,100,347.29. This represents a 26.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Andrea Difabio sold 1,342 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $74,118.66. Following the sale, the insider owned 7,301 shares in the company, valued at approximately $403,234.23. The trade was a 15.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 296,707 shares of company stock valued at $17,845,365. Company insiders own 4.07% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $33,000. Blue Trust Inc. lifted its holdings in shares of Xenon Pharmaceuticals by 2,560.7% in the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 717 shares in the last quarter. Danske Bank A S bought a new position in shares of Xenon Pharmaceuticals in the third quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $43,000. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Xenon Pharmaceuticals in the third quarter valued at approximately $39,000. Institutional investors own 95.45% of the company’s stock.

Key Stories Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Royal Bank of Canada raised its price target on Xenon Pharmaceuticals from $80 to $82 and reaffirmed an outperform rating, signaling confidence in further upside. RBC price target update
• Positive Sentiment: Xenon reported Q1 2026 earnings of -$1.17 per share, matching analyst expectations and reducing uncertainty around the quarter. The company also said it provided a business update alongside the results. Q1 2026 financial results and business update
• Neutral Sentiment: Needham & Company lowered its price target slightly from $80 to $78 but kept a buy rating, which still points to substantial upside from current levels. Needham price target update
• Neutral Sentiment: The company’s earnings call transcript and earnings snapshot are drawing investor attention, but no additional major surprise was highlighted in the available items. Q1 2026 earnings call transcript

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.